Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract IA46: Towards implementation of T-cell therapy in pancreatic cancer

Rienk Offringa, Isabel Poschke, Michael Volkmar, Oliver Strobel, Frank Bergmann, Niels Halama, Dirk Jäger, Ugur Sahin and Markus Büchler
Rienk Offringa
1German Cancer Research Center, Heidelberg, Germany,
2University of Heidelberg, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Poschke
1German Cancer Research Center, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Volkmar
1German Cancer Research Center, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Strobel
2University of Heidelberg, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Bergmann
2University of Heidelberg, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niels Halama
3National Center for Tumor Diseases, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Jäger
3National Center for Tumor Diseases, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ugur Sahin
4BioNTech Inc., Mainz, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Büchler
2University of Heidelberg, Heidelberg, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-IA46 Published January 2016
  • Article
  • Info & Metrics
Loading
Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY

Abstract

In contrast to the general belief that pancreatic ductal adenocarcinoma is a poorly immunogenic tumor, we found cumulative evidence for an adaptive immune response in this aggressive cancer type. Immunohistochemistry reveals prominent T-cell infiltrates in the majority (~ 70%) of tumor biopsies, and these tumor-infiltrating lymphocytes (TILs) can be isolated and expanded ex vivo with similar efficiency as those isolated from melanoma. Furthermore, comparison of the T-cell receptor repertoire between TIL and PBMC isolates from patients points at the selective expansion of T-cell subsets in the tumors. Finally, in ~ 50% of tumor specimen, T-cell infiltration is accompanied by the presence of tertiary lymphoid structures that comprise areas rich in CD3+ T-cells and CD208+ dendritic cells as well as areas rich in B-cells and follicular dendritic cells.

Based on these findings, our current efforts aim at:

- Evaluating neoadjuvant treatment with agonist immunostimulatory antibodies as a means to mobilize this pre-existing immune response in patients with primary resectable disease*

- Analysis of the anti-tumor reactivity and antigen-specificity of TCR-species that are prominently enriched in the tumor as compared to PBMC.

- Exploration of TIL therapy for treatment of recurrent disease.

* Clinical trial in context of FP7 EU IACT program; Immunostimulatory Antibodies for Cancer Treatment

Citation Format: Rienk Offringa, Isabel Poschke, Michael Volkmar, Oliver Strobel, Frank Bergmann, Niels Halama, Dirk Jäger, Ugur Sahin, Markus Büchler. Towards implementation of T-cell therapy in pancreatic cancer. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr IA46.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 4 (1 Supplement)
January 2016
Volume 4, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract IA46: Towards implementation of T-cell therapy in pancreatic cancer
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract IA46: Towards implementation of T-cell therapy in pancreatic cancer
Rienk Offringa, Isabel Poschke, Michael Volkmar, Oliver Strobel, Frank Bergmann, Niels Halama, Dirk Jäger, Ugur Sahin and Markus Büchler
Cancer Immunol Res January 1 2016 (4) (1 Supplement) IA46; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-IA46

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract IA46: Towards implementation of T-cell therapy in pancreatic cancer
Rienk Offringa, Isabel Poschke, Michael Volkmar, Oliver Strobel, Frank Bergmann, Niels Halama, Dirk Jäger, Ugur Sahin and Markus Büchler
Cancer Immunol Res January 1 2016 (4) (1 Supplement) IA46; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-IA46
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Oral Presentations - Invited Abstracts

  • Abstract IA10: Combination checkpoint blockade
  • Abstract IA44: Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome
  • Abstract IA14: Engaging T cells against cancer: BLINCYTO® and beyond – the BiTE® platform
Show more Clinical Trials of Cancer Immunotherapies: Oral Presentations - Invited Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement